Impax Laboratories has licensed US commercial rights to the tablet, orally disintegrating tablet and nasal spray formulations of AstraZeneca’s migraine drug Zomig® (zolmitriptan) for a total of US$130 M in quarterly payments plus tiered royalties on future sales. The deal also provides Impax with non-exclusive rights to develop new products containing zolmitriptan and market them using the Zomig brand name. The addition of Zomig will support the commercial growth of Impax’s branded products business.